Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality ImprovementRelease Date:Quality Improvement Oncology Kazakhstan Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer CareEducation Oncology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative StrategiesRelease Date:Quality Improvement Oncology All Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology PracticeRelease Date:Education Oncology USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology China, France, Germany, Italy, Japan, Spain, Turkey, United Kingdom Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding DisordersRelease Date:Research Rare Disease All Title Grant Type Focus Area Country Application Due Date Innovative Digital Health Projects to increase the Quality of Life (QoL) of Multiple Myeloma (MM) patientsRelease Date:Quality Improvement Oncology Italy 2024 RD Global Monitoring anti-TFPI RESRelease Date:Research Rare Disease All Call for Independent Medical Education Grant Applications Oncology – Urothelial Carcinoma (UC)Education Oncology All Health Services Research to Improve Management of mBC Patients Treated with TucatinibRelease Date:Research Oncology All Addressing Multiple Myeloma Gaps in Care for Patients in Latin AmericaRelease Date:Partner: International Myeloma FoundationEducation Oncology Argentina, Brazil, Colombia, Mexico Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Management of Atopic Dermatitis / Alopecia AreataRelease Date:Education Inflammation & Immunology USA Improving the Care Process for Patients with Advanced Prostate CancerRelease Date:Partner: The American Urological Association Education and Research, Inc.; AstellasQuality Improvement Oncology USA Optimizing Care for patients with locally advanced or metastatic Urothelial Carcinoma (la/mUC)Release Date:Quality Improvement Oncology Canada Prospective Surveillance and Burden of Disease for RSV-Related Respiratory Tract Infections in Taiwanese Pediatric PopulationRelease Date:Research Vaccines Taiwan PARP-Inhibitor Combination Therapies: Personalized Treatment for Patients with Metastatic Castration-Resistant Prostate CancerRelease Date:Education Oncology Canada Developing Educational Initiatives for ALK+ Metastatic Non-small Cell Lung Cancer Tyrosine Kinase Inhibitors TherapyRelease Date:Education Oncology Canada